ArticleLipids2015
The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters.
Article in Lipids, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- TRIM29-dependent AKR1B10 degradation ameliorates MASH.Science advances · 2026Article
- Exploring the Distinct Regulatory Actions and Molecular Pathways of Coptisine Through Network Pharmacology: Insights Into Its Influence on Platelet Activation and Thrombus Development.Food science & nutrition · 2026Article
- Current status and research trends of coptisine: a bibliometric analysis (1995 to 2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review.Molecular biology reports · 2022Review
- Isoquinoline Alkaloids fromInternational journal of molecular sciences · 2022Article
- Biological Response Profiling Reveals the Functional Differences of Main Alkaloids in Rhizoma Coptidis.Molecules (Basel, Switzerland) · 2021Article
- Biologically active isoquinoline alkaloids covering 2014-2018.Medicinal research reviews · 2020Review
- Simultaneous Qualitative and Quantitative Evaluation of the Coptidis Rhizoma and Euodiae Fructus Herbal Pair by Using UHPLC-ESI-QTOF-MS and UHPLC-DAD.Molecules (Basel, Switzerland) · 2020Article
- Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway.International journal of molecular sciences · 2020Article
- Coptisine Alleviates Pristane-Induced Lupus-Like Disease and Associated Kidney and Cardiovascular Complications in Mice.Frontiers in pharmacology · 2020Article
- Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review.Journal of cellular and molecular medicine · 2019Review
- Effect of emodin on chondrocyte viability in anExperimental and therapeutic medicine · 2018Article
- Coptisine-induced inhibition of Helicobacter pylori: elucidation of specific mechanisms by probing urease active site and its maturation process.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Novel Inhibitor Discovery ofMolecules (Basel, Switzerland) · 2018Article
- Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis.Cholesterol · 2018Review
- Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo.Scientific reports · 2017Article
- Rhizoma Coptidis: A Potential Cardiovascular Protective Agent.Frontiers in pharmacology · 2016Review
- Effect of Rhizoma coptidis (Huang Lian) on Treating Diabetes Mellitus.Evidence-based complementary and alternative medicine : eCAM · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current work was conducted to evaluate the cholesterol-lowering effect of coptisine extracted from Rhizoma coptidis in Syrian golden hamsters. The safety results indicated that coptisine was a safe and low-toxic compound. Coptisine showed a beneficial effect in the abnormal serum lipid levels induced by a high-fat and high-cholesterol diet (HFHC): at a concentration of 70.05 mg/kg, coptisine significantly led to a decrease in total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-c) levels by 26.70, 15.38, and 22.22 %, respectively, and high-density lipoprotein cholesterol (HDL-c) was increased by 41.74 % in serum of hamsters (p < 0.01). In addition, total bile acid (TBA) levels in feces of hamsters were elevated after coptisine administration. Further investigation has suggested that the mRNA and protein expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) in the liver of hamsters was down-regulated by high-dosage coptisine treatment (p < 0.05); mRNA and protein expression of low-density lipoprotein receptor (LDLR) and cholesterol 7α-hydroxylase (CYP7A1) were dramatically up-regulated by coptisine administration. The apical sodium-dependent bile salt transporter expression was down-regulated in the coptisine-treated animals, but showed no significant differences from the HFHC groups. Taken together, our results demonstrate that a high dosage of coptisine could inhibit cholesterol synthesis via suppressing the HMGCR expression and promoting the use and excretion of cholesterol via up-regulating LDLR and CYP7A1 expression. These findings suggest a critical role for coptisine in anti- hypercholesterolemia, and thus it needs to be considered as a potential natural cholesterol lowering agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.